Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremy D Waight

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Nature Communications|August 18, 2023
TIGIT can inhibit T cell activation via ligation-induced nanoclusters, independent of CD226 co-stimulationJonathan D Worboys, Katherine N Vowell, Roseanna K Hare, et al.
Plos One|April 5, 2018
Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibodyRandi B Gombos, Ana Gonzalez, Mariana Manrique, et al.
Cancer Research Communications|August 18, 2023
Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint BlockadeSapna Yadavilli, Jeremy D Waight, Sara Brett, et al.
EMBO Molecular Medicine|December 29, 2020
Immunodynamics of explanted human tumors for immuno-oncologyAgathe Dubuisson, Jean-Eudes Fahrner, Anne-Gaëlle Goubet, et al.
Cancer Discovery|July 31, 2024
Botensilimab, an Fc-Enhanced Anti-CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional ImmunotherapyDhan Chand, David A Savitsky, Shanmugarajan Krishnan, et al.
Frontiers in Oncology|November 24, 2022
NK cells with decreased expression of multiple activating receptors is a dominant phenotype in pediatric patients with acute lymphoblastic leukemiaLucero Valenzuela-Vázquez, Juan Carlos Nuñez-Enriquez, Jacqueline Sánchez-Herrera, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Nature Communications|August 18, 2023
TIGIT can inhibit T cell activation via ligation-induced nanoclusters, independent of CD226 co-stimulationJonathan D Worboys, Katherine N Vowell, Roseanna K Hare, et al.
Plos One|April 5, 2018
Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibodyRandi B Gombos, Ana Gonzalez, Mariana Manrique, et al.
Cancer Research Communications|August 18, 2023
Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint BlockadeSapna Yadavilli, Jeremy D Waight, Sara Brett, et al.
EMBO Molecular Medicine|December 29, 2020
Immunodynamics of explanted human tumors for immuno-oncologyAgathe Dubuisson, Jean-Eudes Fahrner, Anne-Gaëlle Goubet, et al.
Cancer Discovery|July 31, 2024
Botensilimab, an Fc-Enhanced Anti-CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional ImmunotherapyDhan Chand, David A Savitsky, Shanmugarajan Krishnan, et al.
Frontiers in Oncology|November 24, 2022
NK cells with decreased expression of multiple activating receptors is a dominant phenotype in pediatric patients with acute lymphoblastic leukemiaLucero Valenzuela-Vázquez, Juan Carlos Nuñez-Enriquez, Jacqueline Sánchez-Herrera, et al.
Pageof 2